Tepnel Shareholders OK Gen-Probe Takeover | GenomeWeb

NEW YORK (GenomeWeb News) – Shareholders of Tepnel Life Sciences have approved the acquisition of the firm by Gen-Probe.

Gen-Probe said today that more than 99 percent of Tepnel shareholders voted in favor of the deal, which was announced in late January. Under terms of the transaction, Gen-Probe will pay 27.1 pence ($.386) per share in cash for each share of Tepnel outstanding — valuing the deal at $132.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.